Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
LACQ Leisure Acquisition Corp
BAC Bank of America Corp
TIF Tiffany & Co
SE Sea Ltd
NRIM Northrim BanCorp Inc
TTC Toro Co
TRTX TPG RE Finance Trust Inc
TRTC Terra Tech Corp
TRMB Trimble Inc
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Price
Delayed
$76.41
Day's Change
1.70 (2.28%)
Bid
--
Ask
--
B/A Size
--
Day's High
76.49
Day's Low
73.95
Volume
(Heavy Day)

Today's volume of 1,416,913 shares is on pace to be much greater than GILD's 10-day average volume of 7,351,351 shares.

1,416,913

GILD's position in the Biotechnology industry

Industry PeersGILDABBVAMGNREGNALXN

Summary

Company ProfileGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and...
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are...
Go to ABBV summary
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products...
Go to AMGN summary
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The...
Go to REGN summary
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS...
Go to ALXN summary
52-Week Change

VS. INDUSTRY
10.27%
37.48%
38.59%
108.02%
-13.72%
Market Cap

VS. INDUSTRY
$93.7B
$172.6B
$148.0B
$65.6B
$24.0B
Beta

VS. INDUSTRY
0.7
0.8
0.9
0.6
1.5
Dividend Yield

VS. INDUSTRY
3.64%
4.82%
2.54%
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
19.20x
17.33x
19.71x
32.19x
10.22x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$22.7B
$34.1B
$24.0B
$8.0B
$5.3B
Profit Margin

VS. INDUSTRY
21.72%
24.77%
32.02%
28.56%
44.83%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
-10.51%
36.83%
13.96%
44.00%
26.84%
Revenue Growth (TTM)

VS. INDUSTRY
1.77%
4.32%
0.91%
21.42%
22.00%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.